CMO deal has U.K. bioprocess focus

Discovery and development service provider AMRI has enhanced its manufacturing service offerings through the acquisition of Excelsyn, a U.K.-based contractor for big pharma, specialty pharma and biotechnology customers in Europe, Asia and North America.

Excelsyn boasts rapid response manufacturing services, thanks to a process that speeds in-plant product changeovers. The process capitalizes on flexibility among batch reactors, says an AMRI spokesperson. Reactors can be independently connected and modified to meet the needs of specific processes less expensively than is the case with fixed-reactor trains. The Excelsyn 14-acre site contains a lab, pilot plant and large scale manufacturing facilities.

Excelsyn also provides AMRI access to the U.K. and European markets, which it had been seeking. The company anticipates a boost to its development and manufacturing work, especially in the production of chemical intermediates.

- see the announcement

Suggested Articles

The partnership aims to make the production of vaccines that use adenovirus as vectors more cost-effective and contamination-free.

The FDA hit New Jersey-based CMO Tris Pharma with a warning letter, citing significant violations.

Celltrion remains optimistic it will get U.S. approval for its two biosimilar drugs, Rituxan and Herceptin, by the end of the year.